IQVIA Institute for Human Data Science

Drug approvals are just the beginning. A new report from IQVIA Institute reveals that biologics and small molecules continue to evolve well beyond their first approval: ✔ Only 31% of biologic approvals happen within the first year of launch, 15% occur after 13 years. ✔ Small molecules see 36% of approvals in Year 1, while 15% happen after 9 years. ✔ The takeaway? Drug innovation is an ongoing process that continues long after first approval and requires long-term investment. How can we continue fostering these post-approval advancements in today’s evolving policy landscape? View IQVIA Institute's full report on Proliferation of Innovation Over Time: https://bit.ly/41axGiZ. #DrugDevelopment #Biologics #ClinicalInnovation

Navigating the complexities of #CancerCare requires efficient referral pathways, especially for advanced treatments such as radioligand therapies (RLTs). IQVIA Institute's report, Developing Efficient Patient Referral Pathways for Radioligand Therapies, explores the current landscape and highlights key challenges: ➡️ Limited Diagnostic Resources: Access to diagnostic tools, such as PSMA PET-CT scans, is uneven across regions. ➡️ Infrastructure Constraints: The availability of centers equipped to administer RLTs varies, impacting patient access. Understanding and addressing these barriers is crucial for improving patient outcomes. For proposed solutions, read the full report: https://bit.ly/3F1BImg.

In a recent video, Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, introduces the 2025 Indicators of Progress for the Life Sciences sector - a research brief published in Jan 2025. This comprehensive analysis outlines key factors poised to shape the industry's trajectory in the coming year. The research brief identifies critical indicators, including enhancing trust in life sciences companies, reducing patient out-of-pocket costs, expanding access to healthcare services, and revitalizing growth in the emerging biopharma sector. These markers serve as benchmarks to assess the sector's advancement by the end of 2025. To explore these indicators in detail and understand their potential impact, access the research brief: https://lnkd.in/dt4ZTJWE

Yesterday, I moderated IQVIA Institute's webinar on Understanding the Impact of CMS Prescription Drug Negotiations on Patient Out-of-Pocket Costs. In this clip, I share a quick recap of our conversation, highlighting key insights and the diverse stakeholders affected by these policy changes. Appreciate the insightful contributions from Kirsten Axelsen, MS; Dan Leonard, MA; Robert Popovian, PharmD, MS; and Luke Greenwalt, MBA, as well as Conrad Bhamani for presenting IQVIA Institute’s latest data-driven analysis on this evolving landscape. If you missed the session, I’d love to hear your thoughts: How do you see these negotiations shaping access, affordability, and innovation in healthcare? Watch on-demand: https://lnkd.in/eYuY2a-T.  #HealthcarePolicy #PharmaSpending #PatientAccess

In recognition of #NationalCancerPreventionMonth, we highlight key findings from the IQVIA Institute's Global Oncology Trends 2024: Outlook to 2028 report: 🟢 Rising Cancer Incidence: Projections indicate that annual global cancer cases will increase by over 12 million, reaching 32 million by 2050 🟢 Advancements in Treatment: In 2023, 25 novel active substances (NASs) for oncology were launched globally, totaling 193 since 2014 These insights underscore the challenges and progress in the fight against cancer. https://bit.ly/3EJ5fRP #CancerPrevention #Oncology

IQVIA Institute for Human Data Science has released an analysis detailing how drug innovation progresses beyond initial FDA approvals. The report on the Proliferation of Innovation Over Time looks at the frequency, timing, and clinical significance of post-approval expansions. It offers valuable insights into the potential effects of policies like the Inflation Reduction Act's Medicare Drug Price Negotiation Program. Understanding these trends is essential for stakeholders navigating the evolving landscape of drug development: https://bit.ly/412nwRG. #DrugDevelopment #DataScience #DrugInnovation

What can global new active substances (NAS) approval rates tell us about the regulatory landscape in Europe, Japan, and the United States? IQVIA Institute’s Assessing Availability of New Drugs in Europe, Japan, and the U.S. report examines the approval patterns for 545 NASs between 2014 and 2022. While nearly half of these NASs gained approval across all three regions, the U.S. leads with the highest overall approval rate at 89%, followed by the EU at 73% and Japan at 63%. This analysis sheds light on the pace of innovation and the unique pathways to patient access in these markets, offering insights into how regulatory processes shape drug availability. https://bit.ly/4k1k9Tq #LifeSciences

Stay informed with the latest insights from the IQVIA Institute—our new monthly newsletter delivers key updates on research, events, and trends shaping the life sciences industry. What’s Inside? 🔹Latest publications on biosimilars, digital health, and healthcare policy 🔹Upcoming webinars featuring expert discussions on industry trends 🔹Blogs and videos breaking down complex topics into actionable insights Don't miss an issue—subscribe today to the IQVIA Institute and stay ahead of the latest developments. https://bit.ly/3QhS1hq #LifeSciences #HealthcareInnovation #Pharma #HealthTech

Join us in one week to understand the real impact of CMS drug price negotiations. Lower drug prices don’t always mean lower out-of-pocket costs for patients. Cost-sharing structures, formulary decisions, and other market forces could lead to unexpected financial burdens. What does this mean for patients, payers, and the broader healthcare system? 📅 Tuesday, Feb. 18 | 10 – 11:30 a.m. EST Register now: https://bit.ly/3QfT41m. #HealthcarePolicy #DrugPricing #Medicare #Pharma

The U.S. biosimilar market is at a crossroads. While biosimilars have already generated billions in savings, long-term sustainability is not guaranteed. Exhibit 13 from our latest report highlights key challenges threatening biosimilar adoption, including: 🔵 Regulatory hurdles that delay approval and raise costs 🔵 Market uncertainty slowing biosimilar adoption 🔵 High investment costs limiting manufacturer entry 🔵 Interchangeability confusion affecting provider and payer trust 🔵 Reimbursement and policy challenges impacting access If all biologics losing patent protection in the next 10 years had biosimilar alternatives at expiry, the U.S. healthcare system could see an additional $189Bn in savings. Check out the details in our latest report: https://bit.ly/3WXfCI5 #Biosimilars #DrugPricing #Pharma #HealthcarePolicy